ARTIST: an activated method in internal coordinate space for sampling protein energy landscapes

Autor: Yun, Mr, Lavery, R., Mousseau, N., Zakrzewska, K., Derreumaux, P.

We present the first applications of an activated method in internal coordinate space for sampling all-atom protein conformations, the activation-relaxation technique for internal coordinate space trajectories (ARTIST). This method differs from all p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______166::6c3779e04bcb524d055cb8eee46c6119
https://hal.archives-ouvertes.fr/hal-00313389

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer.

Autor: Lim SM; Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea., Schalm SS; Blueprint Medicines Corporation, Cambridge, MA, USA., Lee EJ; Department of Biomedical Science Institute, Graduated School of Medical Science, Brain Korea 21 FOUR Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea., Park S; JEUK Institute for Cancer Research, JEUK Co. Ltd., Seoul, Republic of Korea., Conti C; Blueprint Medicines Corporation, Cambridge, MA, USA., Millet YA; Blueprint Medicines Corporation, Cambridge, MA, USA., Woessner R; Blueprint Medicines Corporation, Cambridge, MA, USA., Zhang Z; Blueprint Medicines Corporation, Cambridge, MA, USA., Tavera-Mendoza LE; Blueprint Medicines Corporation, Cambridge, MA, USA., Stevison F; Blueprint Medicines Corporation, Cambridge, MA, USA., Albayya F; Blueprint Medicines Corporation, Cambridge, MA, USA., Dineen TA; Blueprint Medicines Corporation, Cambridge, MA, USA., Hsieh J; Blueprint Medicines Corporation, Cambridge, MA, USA., Oh SY; Department of Biomedical Science Institute, Graduated School of Medical Science, Brain Korea 21 FOUR Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea., Zalutskaya A; Blueprint Medicines Corporation, Cambridge, MA, USA., Rotow J; Dana-Farber Cancer Institute, Boston, MA, USA., Goto K; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Lee DH; Department of Oncology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Republic of Korea., Yun MR; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Cho BC; Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.

Publikováno v: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2024 Oct 21; Vol. 16, pp. 17588359241280689. Date of Electronic Publication: 2024 Oct 21 (Print Publication: 2024).